Evommune (EVMN) Net Income towards Common Stockholders (2024 - 2026)
Evommune (EVMN) reported Net Income towards Common Stockholders of -$21.7 million for Q1 2026, down 50.18% year-over-year from -$43.5 million in Q1 2025, and up 23.34% quarter-over-quarter from -$28.3 million in Q4 2025.
Evommune (EVMN) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
Evommune (EVMN) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$21.7 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$21.7 million, down 50.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$76.9 million (changed N/A YoY), and the FY2025 annual result was -$77.8 million, down 16.45% from the prior year.
- Net Income towards Common Stockholders improved to -$21.7 million in Q1 2026 per EVMN's latest filing, from -$28.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$12.5 million in Q3 2025 and troughed at -$28.3 million in Q4 2025.
- A 3-year average of -$18.9 million and a median of -$18.3 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders gained 21.62% in 2025, then slumped 50.18% in 2026.
- A 3-year view of Net Income towards Common Stockholders shows it stood at -$20.7 million in 2024, then sank by 36.41% to -$28.3 million in 2025, then climbed by 23.34% to -$21.7 million in 2026.
- Business Quant data shows EVMN's Net Income towards Common Stockholders at -$21.7 million in Q1 2026, -$28.3 million in Q4 2025, and -$12.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - | -21.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.67 Mn |
| Dec 31, 2025 | -28.27 Mn |
| Sep 30, 2025 | -12.48 Mn |
| Mar 31, 2025 | -14.43 Mn |
| Dec 31, 2024 | -20.73 Mn |
| Sep 30, 2024 | -15.92 Mn |